Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids

14 Jul 2020

Abstract excerpt

Drug combinations have been proposed to combat drug resistance, but putative treatments are challenged by low bench-to-bed translational efficiency. To explore the effect of cell culture format and readout methods on identification of synergistic drug combinations in vitro, we studied response to 21 clinically relevant drug combinations in standard planar (2D) layouts and physiologically more relevant spheroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3D Printing in Biomedical Research
Share to Cancer Cells and Metastasis
Share to Mathematical Biology Tumor Growth

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32665693
DOI: 10.1038/s41598-020-68441-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroidsPMID 32665693Read ↗

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.Semantic proximity Read ↗

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read ↗

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.Semantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

A cell-based high-throughput screen to identify synergistic TRAIL sensitizersSemantic proximity Read ↗

Cell line modeling for systems medicine in cancers (Review)Semantic proximity Read ↗

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read ↗

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.Semantic proximity Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Semantic proximity Read ↗

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergismsSemantic proximity Read ↗

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.